Cytoprotective and supportive care agents:
Indications for XERMELO:
In combination with somatostatin analog (SSA) therapy, to treat carcinoid syndrome diarrhea in adults inadequately controlled by SSA therapy.
Take with food. 250mg 3 times daily.
Monitor for constipation and/or severe, persistent, or worsening abdominal pain; discontinue if develops. Moderate and severe hepatic impairment: not recommended. ESRD requiring dialysis: not studied. Pregnancy. Nursing mothers: monitor infant for constipation.
Tryptophan hydroxylase inhibitor.
May antagonize CYP3A4 (eg, midazolam) or CYP2B6 substrates (eg, bupropion, efavirenz); monitor and consider increasing dose of interacting drug if necessary. Antagonized by short-acting octreotide; if concomitant use is necessary, give dose ≥30mins after Xermelo.
Nausea, headache, increased GGT, depression, flatulence, decreased appetite, peripheral edema, pyrexia.
Generic Drug Availability:
Tabs—84 (monthly case)